Skip to content

Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder

A Prospective Double Blind Randomized Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00134446
Enrollment
40
Registered
2005-08-24
Start date
2004-03-31
Completion date
Unknown
Last updated
2005-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-Traumatic Stress Disorders

Keywords

post traumatic stress disorder, PTSD, trauma, transcranial magnetic stimulation, randomized clinical trial

Brief summary

The purpose of this study is to determine if transcranial magnetic stimulation at 1 HZ to the right frontal cortex will decrease the symptoms of post-traumatic stress disorder (PTSD).

Detailed description

Post-traumatic stress disorder (PTSD) is a psychiatric disorder that is common in the general population. PTSD symptoms include re-experiencing the traumatic event, avoidance of reminders of the trauma, and increased arousal. The primary treatments of PTSD are psychotherapy and antidepressant medications. While both are effective, many patients continue to have significant symptoms. Repetitive Transcranial Magnetic Stimulation (rTMS) is a new research and treatment modality that uses a small powerful electromagnet to directly stimulate the brain. This stimulation may increase or decrease brain activity. The treatments have been shown to be effective in other disorders such as depression. Initial treatment of patients with PTSD using rTMS has been hopeful. This study is the first randomized controlled trial to examine the efficacy of rTMS for PTSD. This study would be the first randomized placebo controlled trial to examine the efficacy of Transcranial Magnetic Stimulation (rTMS) for PTSD. The primary hypothesis is that there will be significant improvement in the patients' PTSD symptoms from pre-treatment to post-treatment with rTMS. A secondary hypothesis is that the patients' co-morbid depressive symptoms will improve from pre-treatment to post-treatment. Forty subjects with PTSD will be recruited from the White River Junction VAMC. Patients will be randomly assigned to receive either active rTMS or sham rTMS. Patients, staff performing the treatments, and staff completing the assessments will all be blinded to active or sham treatment.

Interventions

DEVICEtranscranial magnetic stimulation

Sponsors

White River Junction Veterans Affairs Medical Center
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* PTSD diagnosis on standardized assessment * Medically stable * Eligible veteran of United States (US) military

Exclusion criteria

* Active substance abuse * History of seizures * Metal in head or neck

Design outcomes

Primary

MeasureTime frame
Clinician-Administered PTSD Scale (CAPS)

Secondary

MeasureTime frame
PTSD Clinician Checklist (PCL)
Beck Depression Inventory (BDI)
State-Trait Anxiety Inventory (STAI)
Side Effect Checklist
Brief Cognitive Examination

Countries

United States

Contacts

Primary ContactBradley V Watts, MD
bradley.v.watts@dartmouth.edu802-295-9363

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026